Giane 35 (Box) 21pcs

Indications of Giane 35

Giane 35, a combination of two hormone drugs, is used to treat polycystic ovarian syndrome (PCOS) symptoms include excessive hair growth (hirsutism), acne, and irregular menstrual cycles. Avoid using any other contraceptive pills since it also functions as a contraceptive.

Pharmacology

Cyproterone is a steroid that has antiandrogenic, progestogenic, and antigonadotrophic properties. Its antiandrogenic action is achieved by inhibiting androgen receptors. It also has a negative feedback impact on the hypothalamic-pituitary-ovarian circuits, which decreases androgen production. The estrogen component (Ethinylestradiol) raises levels of sex hormone-binding globulin (SHBG) and consequently lowers androgen levels in the blood. SHBG levels are not reduced by cyproterone.

Cyproterone, when administered alone in women, causes menstrual cycle disruptions, which are prevented when coupled with Ethinylestradiol. When taken in a cyclic pattern, this pill offers the extra benefit of preventing ovulation and possible pregnancy.

After oral administration, the components of this tablet are promptly absorbed. After 6 to 12 days of daily dosage, a 4-fold rise in plasma levels occurs due to Cyproterone's lengthy terminal half-life. Long-term treatment with this substance (36 months) had no discernible effect on lipid metabolism. There was a tendency toward higher plasma cholesterol and triglyceride levels. Low-density lipoprotein (LDL) levels fell slightly, but high-density lipoprotein (HDL) levels rose (HDL).

Dosage & Administration

This tablet should not be prescribed solely for its contraceptive properties. If patient compliance is uncertain and contraception is necessary, then a supplementary nonhormonal contraceptive method should be considered.

• First Treatment Course: The patient is instructed to take 1 tablet daily for 21 consecutive days beginning on day 1 of her menstrual cycle. (For the first cycle only the first day of menstrual flow is considered Day 1). The tablets are then discontinued for 7 days (1 week). Withdrawal bleeding should usually occur during the period that the patient is off the tablets. The first cycle will be somewhat shorter than usual, whereas all following cycles will last 4 weeks. The patient should be instructed to take the first tablet from the blister pack out of the section marked with the corresponding day (for example "Mon" for Monday) of the week and swallow it with some liquid. The patient should be instructed to take the tablet at the same time each day.
• Subsequent Courses: The patient begins her next and all subsequent 21-day courses of tablets (following the same 21 days on, 7 days off) on the same day of the week that she began her first course. She begins taking her tablets 7 days after discontinuation, regardless of whether or not withdrawal bleeding is still in progress.
• Treatment should be continued for several months, since improvement may not be observed for at least 3 months. The need to continue treatment with This tablet should be evaluated periodically by the treating physician. This drug should be discontinued 3 to 4 cycles after signs have completely resolved.
• Pregnancy should be ruled out before continuing treatment with This tablet in patients who have missed a menstrual period, if pregnancy is suspected, medication should be discontinued.
• Missed dose: If the patient forgets to take a tablet at the usual time, the tablet may be taken within the next 12 hours. If more than 12 hours have elapsed from the time of usual administration, the patient must discard the missed tablet and continue to take the remaining tablets in the pack at the usual time in order to avoid premature withdrawal bleeding during this cycle. A supplementary nonhormonal method of contraception must be employed until the pack is empty to prevent pregnancy which would necessitate immediate discontinuation of this treatment.

Interaction of Giane 35

Ampicillin, analgesics, antihistamines, antimigraine preparations, Chloramphenicol, Griseofulvin, Isoniazid, Neomycin, Nitrofurantoin, Penicillin V, Phenylbutazone, Sulfonamides, and Tetracycline may impair the effectiveness of this pill and raise the risk of breakthrough bleeding if taken together.

When anticoagulants are used with estrogen/progestogen combos, the anticoagulant impact may be reduced. Ampicillin, analgesics, antihistamines, antimigraine preparations, Chloramphenicol, Griseofulvin, Isoniazid, Neomycin, Nitrofurantoin, Penicillin V, Phenylbutazone, Sulfonamides, and Tetracycline may impair the effectiveness of this pill and raise the risk of breakthrough bleeding if taken together.

When anticoagulants are used with estrogen/progestogen combos, the anticoagulant impact may be reduced. Anti-diabetic medicine may need to be adjusted for diabetics who use estrogen/progestogen combos. It has been observed that taking vitamin C (ascorbic acid) with estrogen/progestogen combinations causes a substantial increase in plasma Ethinylestradiol levels.

Before starting therapy, be sure you're not pregnant. Feminization of male fetuses has happened in animal studies and may occur in humans due to the antiandrogenic effect of this pill.

Contraindications

• Thrombophlebitis, thromboembolic diseases, or a family history of them
• Cerebral vascular disease
• Coronary artery disease or myocardial infarction
• Hepatic adenomas or carcinomas, as well as active liver disease
• cholestatic jaundice in the past
• Breast cancer that is known or suspected
• Estrogen-dependent neoplasia that is known or suspected
• Abnormal vaginal hemorrhage that has gone undiagnosed
• Any eye lesion caused by ophthalmic vascular diseases, such as partial or total blindness or visual field defects.
• If you think you're pregnant or have been told you are,
• Tumors in the liver that have previously been or are now present
• Diabetes mellitus with vascular alterations
• Otosclerosis with worsening during pregnancy is a history.

Side Effect

Bleeding, dizziness, depression, weight gain, headache, edema, breast discomfort, lactation, blood clot, and gallstones are all common adverse effects.

Pregnancy & Lactation

The kids of women who used estrogen/progestogen combos in early pregnancy have been documented to develop fetal defects. As soon as you suspect pregnancy, rule it out. It's possible that using estrogen/progestogen combos when a woman is breastfeeding her baby isn't a good idea. The hormonal components are expelled in breast milk, which might affect the amount and quality of the product. The long-term consequences on a child's development remain unknown. Fluid retention, as well as epilepsy, are possible side effects of this medication.

Precautions & Warnings

Predisposing Factors for Coronary Artery Diseases: The use of estrogen or progestogen combinations has been reported as an additional risk factor in women with predisposing factors for coronary artery disease (such as cigarette smoking, hypertension, hypercholesterolemia, obesity, diabetes, and increasing age). After the age of 35, estrogen or progestogen combinations should only be considered in rare circumstances and after both the patient and the physician have carefully analyzed the risk/benefit ratio.

Thromboembolic and cardiovascular diseases such as thrombophlebitis, pulmonary embolism, cerebrovascular disorders, myocardial ischemia, mesenteric thrombosis, and retinal thrombosis should be stopped as soon as possible. In situations that predispose to venous stasis and vascular thrombosis, such as immobilization following accidents or confinement to bed during long-term sickness, the use of estrogen/progestogen-combination products should be avoided.

Patients with essential hypertension who have well-controlled blood pressure may be administered the medication, but only under strict monitoring. If a substantial increase in blood pressure develops in previously normotensive or hypertensive individuals at any point during the drug's treatment, the medication must be stopped.

Storage Conditions

Keep away from light and moisture in a cool, dry area (below 30° C). Keep out of children's reach.